{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:36:13Z","timestamp":1789828573396,"version":"4.0.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["8,447,384"],"award-info":[{"award-number":["8,447,384"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["10,215,830"],"award-info":[{"award-number":["10,215,830"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["11,051,902"],"award-info":[{"award-number":["11,051,902"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ucl.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:24:04Z","timestamp":1762345444000},"page":"115-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Focal Therapies for Localized Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Jibriel","family":"Noun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Blachman-Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0094-0143(05)70168-3","article-title":"Intraoperative, perioperative, and long-term complications of radical prostatectomy","volume":"28","author":"Shekarriz","year":"2001","journal-title":"Urol Clin North Am"},{"issue":"12 Suppl","key":"10.1016\/j.ucl.2025.09.010_bib2","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1002\/1097-0142(20000615)88:12+<3009::AID-CNCR17>3.0.CO;2-E","article-title":"Hormone therapy for patients with prostate carcinoma","volume":"88","author":"Klotz","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JU.0000000000003965","article-title":"Long-term second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy","volume":"212","author":"St-Laurent","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.010_bib5","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMcibr0905562","article-title":"The index lesion and the origin of prostate cancer","volume":"361","author":"Ahmed","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.juro.2012.06.011","article-title":"Correlation of magnetic resonance imaging tumor volume with histopathology","volume":"188","author":"Turkbey","year":"2012","journal-title":"J Urol"},{"issue":"7547","key":"10.1016\/j.ucl.2025.09.010_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2217\/fon-2016-0201","article-title":"MRI-Guided focal therapy of prostate cancer","volume":"13","author":"Mathew","year":"2017","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.010_bib9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrurol.2010.142","article-title":"Focal therapy in prostate cancer: modalities, findings and future considerations","volume":"7","author":"Lindner","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.010_bib10","doi-asserted-by":"crossref","first-page":"289.e1","DOI":"10.1016\/j.urolonc.2024.04.022","article-title":"Combined holmium laser enucleation of the prostate with high-intensity focused ultrasound in treating patients with localized prostate cancer in a prostate with volume > 60 g: oncological and functional outcomes from single-institution study","volume":"42","author":"Ajami","year":"2024","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1089\/end.2021.0866","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer: a systematic review","volume":"36","author":"Dora","year":"2022","journal-title":"J Endourol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF00256151","article-title":"Rectal temperature monitoring during neodymion-YAG laser irradiation for prostatic carcinoma","volume":"12","author":"Beisland","year":"1984","journal-title":"Urol Res"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.010_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10439-005-8981-8","article-title":"Tissue ablation with irreversible electroporation","volume":"33","author":"Davalos","year":"2005","journal-title":"Ann Biomed Eng"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/cryo.1998.2115","article-title":"Mechanisms of tissue injury in cryosurgery","volume":"37","author":"Gage","year":"1998","journal-title":"Cryobiology"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00345-010-0554-2","article-title":"Photodynamic therapy for focal ablation of the prostate","volume":"28","author":"Arumainayagam","year":"2010","journal-title":"World J Urol"},{"issue":"37","key":"10.1016\/j.ucl.2025.09.010_bib16","doi-asserted-by":"crossref","first-page":"18590","DOI":"10.1073\/pnas.1906929116","article-title":"Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study","volume":"116","author":"Rastinehad","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.010_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jvir.2020.10.002","article-title":"Early results of unilateral prostatic artery embolization as a focal therapy in patients with prostate cancer under active surveillance: cancer prostate embolisation, a pilot study","volume":"32","author":"Frandon","year":"2021","journal-title":"J Vasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.euf.2023.02.005","article-title":"Prostatic artery embolization in patients with prostate cancer: a systematic review","volume":"10","author":"Burkhardt","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib102","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41391-022-00577-8","article-title":"Transperineal targeted microwave ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study","volume":"26","author":"Chiu","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib103","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/JU.0000000000001567","article-title":"Prostate radiofrequency focal ablation (ProRAFT) trial: a prospective development study evaluating a bipolar radiofrequency device to treat prostate cancer","volume":"205","author":"Orczyk","year":"2021","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/pcan.2017.8","article-title":"Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project","volume":"20","author":"Tay","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2025.09.010_bib20","first-page":"1","article-title":"Identifying the best candidate for focal therapy: a comprehensive review","author":"Ghoreifi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.16360","article-title":"The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer","volume":"134","author":"Rodr\u00edguez-S\u00e1nchez","year":"2024","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","article-title":"Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study","volume":"68","author":"Ahmed","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.010_bib27","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.urolonc.2018.05.022","article-title":"Prostate cancer treatment by the latest focal HIFU device with MRI\/TRUS-fusion control biopsies: a prospective evaluation","volume":"36","author":"von Hardenberg","year":"2018","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.010_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00345-018-2442-0","article-title":"Extra-target low-risk prostate cancer: implications for focal high-intensity focused ultrasound of clinically significant prostate cancer","volume":"37","author":"Annoot","year":"2019","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.juro.2018.07.040","article-title":"Oncologic and functional outcomes of partial gland ablation with high intensity focused ultrasound for localized prostate cancer","volume":"201","author":"Bass","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.010_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.urology.2019.06.043","article-title":"Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-center in the United Kingdom","volume":"133","author":"Johnston","year":"2019","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/JU.0000000000000298","article-title":"Extensive histological sampling following focal therapy of clinically significant prostate cancer with high intensity focused ultrasound","volume":"202","author":"Mortezavi","year":"2019","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.010_bib32","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00345-018-2613-z","article-title":"Oncological long-term outcome of whole gland HIFU and open radical prostatectomy: a comparative analysis","volume":"37","author":"Rosenhammer","year":"2019","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bju.14710","article-title":"Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer","volume":"124","author":"Stabile","year":"2019","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/JU.0000000000001015","article-title":"Prospective evaluation of focal high intensity focused ultrasound for localized prostate cancer","volume":"204","author":"Nahar","year":"2020","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.010_bib35","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s10147-020-01723-9","volume":"25","author":"Shoji","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.010_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/JU.0000000000000506","article-title":"Focal therapy for localized prostate cancer with either high intensity focused ultrasound or cryoablation: a single institution experience","volume":"203","author":"Tourinho-Barbosa","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00345-020-03297-7","article-title":"Focal HIFU therapy for anterior compared to posterior prostate cancer lesions","volume":"39","author":"Huber","year":"2021","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.010_bib38","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41391-020-00315-y","article-title":"Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study","volume":"24","author":"Shah","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/JU.0000000000001787","article-title":"Association between lesion location and oncologic outcomes after focal therapy for localized prostate cancer using either high intensity focused ultrasound or cryotherapy","volume":"206","author":"Stabile","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00345-023-04352-9","article-title":"Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected","volume":"41","author":"Duwe","year":"2023","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib41","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.231473","article-title":"MRI-guided focused ultrasound focal therapy for intermediate-risk prostate cancer: final results from a 2-year phase II clinical trial","volume":"310","author":"Ghai","year":"2024","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2015.12.029","article-title":"Magnetic resonance imaging\u2013guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial","volume":"70","author":"Chin","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21681805.2019.1660707","article-title":"Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer","volume":"53","author":"Anttinen","year":"2019","journal-title":"Scand J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jvir.2019.12.802","article-title":"MR imaging-guided transurethral ultrasound ablation of localized prostate cancer: preliminary experience from a single center in a prospective, multi-center, single-arm clinical trial","volume":"31","author":"Sundaram","year":"2020","journal-title":"J Vasc Intervent Radiol"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.010_bib45","doi-asserted-by":"crossref","first-page":"830.e9","DOI":"10.1016\/j.urolonc.2021.04.022","article-title":"Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)","volume":"39","author":"Lumiani","year":"2021","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bju.15268","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective phase I study","volume":"127","author":"Nair","year":"2021","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-023-01306-6","article-title":"First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study","volume":"23","author":"Peters","year":"2023","journal-title":"BMC Urol"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.010_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/JU9.0000000000000034","article-title":"Durability of functional outcomes after mri-guided transurethral ultrasound ablation of the prostate","volume":"1","author":"Hatiboglu","year":"2023","journal-title":"JU Open Plus"},{"key":"10.1016\/j.ucl.2025.09.010_bib49","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.urolonc.2024.01.234","article-title":"PIVOTAL study of MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer: 5-year follow up","volume":"42","author":"Eggener","year":"2024","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"key":"10.1016\/j.ucl.2025.09.010_bib50","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.urolonc.2024.01.225","article-title":"MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) of localized prostate cancer: single institution experience of treatment efficacy","volume":"42","author":"Bochner","year":"2024","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib51","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.juro.2009.06.035","article-title":"Image guided photothermal focal therapy for localized prostate cancer: phase I trial","volume":"182","author":"Lindner","year":"2009","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib52","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.juro.2016.07.074","article-title":"Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer","volume":"196","author":"Eggener","year":"2016","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.010_bib53","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/ans.15526","article-title":"Magnetic resonance image-guided focal laser ablation in clinically localized prostate cancer: safety and efficacy","volume":"89","author":"Al-Hakeem","year":"2019","journal-title":"ANZ J Surg"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jvir.2018.09.016","article-title":"Focal laser ablation of prostate cancer: results in 120 patients with Low- to intermediate-risk disease","volume":"30","author":"Walser","year":"2019","journal-title":"J Vasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib55","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5152\/dir.2021.20095","article-title":"MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up","volume":"27","author":"Mehralivand","year":"2021","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.ucl.2025.09.010_bib56","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.urology.2021.03.054","article-title":"5-year outcomes following focal laser ablation of prostate cancer","volume":"155","author":"Chao","year":"2021","journal-title":"Urology"},{"issue":"1131","key":"10.1016\/j.ucl.2025.09.010_bib57","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210414","article-title":"Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer","volume":"95","author":"Paxton","year":"2022","journal-title":"Br J Radiol"},{"issue":"15","key":"10.1016\/j.ucl.2025.09.010_bib58","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.3390\/cancers16152620","article-title":"Transperineal laser ablation for focal therapy of localized prostate cancer: 12-month follow-up outcomes from a single prospective cohort study","volume":"16","author":"Iacovelli","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ucl.2025.09.010_bib59","doi-asserted-by":"crossref","unstructured":"Mendez MH, Passoni NM, Pow-Sang J, Jones JS, Polascik TJ. Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. Available at: https:\/\/home.liebertpub.com\/end. 2015;29(10):1193-1198. doi:10.1089\/END.2014.0881.","DOI":"10.1089\/end.2014.0881"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib60","doi-asserted-by":"crossref","first-page":"150.e1","DOI":"10.1016\/j.urolonc.2016.11.008","article-title":"Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: a prospective development study","volume":"35","author":"Valerio","year":"2017","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"key":"10.1016\/j.ucl.2025.09.010_bib61","doi-asserted-by":"crossref","unstructured":"Tay KJ, Polascik TJ, Elshafei A, Tsivian E, Jones JS. Propensity score-matched comparison of partial to whole-gland cryotherapy for intermediate-risk prostate cancer: an analysis of the cryo on-line data registry data. Available at: https:\/\/home.liebertpub.com\/end. 2017;31(6):564-571. doi:10.1089\/END.2016.0830.","DOI":"10.1089\/end.2016.0830"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib62","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1097\/JU.0000000000000456","article-title":"Hemigland cryoablation of localized low, intermediate and high risk prostate cancer: oncologic and functional outcomes at 5 years","volume":"202","author":"Oishi","year":"2019","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eururo.2018.12.030","article-title":"Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry","volume":"76","author":"Shah","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-019-0562-5","article-title":"Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging","volume":"19","author":"Sze","year":"2019","journal-title":"BMC Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib65","article-title":"Feasibility of in-office MRI-targeted partial gland cryoablation for prostate cancer: an IDEAL stage 2A study","volume":"2","author":"Basourakos","year":"2020","journal-title":"BMJ Surg Interv Health Technol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib66","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/JU.0000000000001133","article-title":"Hemigland cryoablation of clinically significant prostate cancer: intermediate-term followup via magnetic resonance imaging guided biopsy","volume":"204","author":"Chuang","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib67","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.euf.2021.04.008","article-title":"Long-term outcomes of focal cryotherapy for low- to intermediate-risk prostate cancer: results and matched pair analysis with active surveillance","volume":"8","author":"Marra","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ucl.2025.09.010_bib68","doi-asserted-by":"crossref","unstructured":"Tan WP, Chang A, Sze C, Polascik TJ. Oncological and functional outcomes of patients undergoing individualized partial gland cryoablation of the prostate: a single-institution experience. Available at: https:\/\/home.liebertpub.com\/end. 2021;35(9):1290-1299. doi:10.1089\/END.2020.0740.","DOI":"10.1089\/end.2020.0740"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.010_bib69","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/pros.24517","article-title":"Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: a Phase II mandatory biopsy-monitored study","volume":"83","author":"Tan","year":"2023","journal-title":"Prostate"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.010_bib70","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.3390\/cancers14122988","article-title":"mpMRI-US fusion-guided targeted cryotherapy in patients with primary localized prostate cancer: a prospective analysis of oncological and functional outcomes","volume":"14","author":"Fern\u00e1ndez-Pascual","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.010_bib71","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.1002\/cam4.5692","article-title":"Cryotherapy for partial gland ablation of prostate cancer: oncologic and safety outcomes","volume":"12","author":"Aker","year":"2023","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib72","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.juro.2016.02.2986","article-title":"Pilot study to assess safety and clinical outcomes of irreversible electroporation for partial gland ablation in men with prostate cancer","volume":"196","author":"Murray","year":"2016","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/pcan.2015.47","article-title":"Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control","volume":"19","author":"Ting","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib74","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/bju.13983","article-title":"Focal irreversible electroporation as primary treatment for localized prostate cancer","volume":"121","author":"van den Bos","year":"2018","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib75","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1148\/radiol.2019181987","article-title":"Image-guided irreversible electroporation of localized prostate cancer: functional and oncologic outcomes","volume":"292","author":"Collettini","year":"2019","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215093","article-title":"Prostate cancer treatment with irreversible electroporation (IRE): safety, efficacy and clinical experience in 471 treatments","volume":"14","author":"Guenther","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.euo.2019.04.008","article-title":"Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort","volume":"3","author":"Blazevski","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib78","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4111\/icu.20210472","article-title":"Focal therapy for prostate cancer with irreversible electroporation: oncological and functional results of a single institution study","volume":"63","author":"Yaxley","year":"2022","journal-title":"Investig Clin Urol"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.010_bib79","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamasurg.2022.2230","article-title":"Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation: a nonrandomized controlled trial","volume":"157","author":"Wang","year":"2022","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib80","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41391-023-00783-y","article-title":"A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer","volume":"27","author":"Zhang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"S4","key":"10.1016\/j.ucl.2025.09.010_bib81","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bju.15946","article-title":"Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer","volume":"131","author":"Scheltema","year":"2023","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib82","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.juro.2016.05.113","article-title":"Final results of a phase I\/II multicenter trial of WST11 vascular targeted photodynamic therapy for hemi-ablation of the prostate in men with unilateral low risk prostate cancer performed in the United States","volume":"196","author":"Taneja","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib83","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2018.05.121","article-title":"Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness","volume":"200","author":"Gill","year":"2018","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib84","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.euf.2018.04.003","article-title":"Medium-term follow-up of vascular-targeted photodynamic therapy of localized prostate cancer using TOOKAD soluble WST-11 (phase II trials)","volume":"5","author":"Noweski","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euf.2021.01.018","article-title":"Vascular-targeted photodynamic therapy in unilateral low-risk prostate cancer in Germany: 2-yr single-centre experience in a real-world setting compared with radical prostatectomy","volume":"8","author":"Flegar","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.010_bib22","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","article-title":"PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI","volume":"34","author":"de Rooij","year":"2024","journal-title":"Eur Radiol"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.010_bib23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.010_bib24","doi-asserted-by":"crossref","first-page":"781.e17","DOI":"10.1016\/j.urolonc.2021.01.027","article-title":"Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: recommendations of an international Delphi consensus","volume":"39","author":"Tan","year":"2021","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib86","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00270-024-03696-y","article-title":"MR-Guided transurethral ultrasound ablation (TULSA)\u2014An emerging minimally invasive treatment option for localised prostate cancer","volume":"47","author":"Fung","year":"2024","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.ucl.2025.09.010_bib87","first-page":"1","article-title":"Development and future prospective of treatment for localized prostate cancer with high-intensity focused ultrasound","volume":"1","author":"Shoji","year":"2022","journal-title":"J Med Ultrason"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.010_bib88","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0090-4295(99)00104-1","article-title":"Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma","volume":"54","author":"Beerlage","year":"1999","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.010_bib89","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2024.02.001","article-title":"The transatlantic recommendations for prostate gland evaluation with magnetic resonance imaging after focal therapy (TARGET): a systematic review and international consensus recommendations","volume":"85","author":"Light","year":"2024","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.010_bib90","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.acra.2024.09.051","article-title":"Comparison of transatlantic recommendations for prostate gland evaluation with MRI after focal therapy (TARGET) and prostate imaging after focal ablation (PI-FAB) for detecting recurrent prostate cancer at prostate MRI","volume":"32","author":"Esengur","year":"2025","journal-title":"Acad Radiol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib91","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.eururo.2020.05.018","article-title":"Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus","volume":"78","author":"Lebastchi","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib92","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/MOU.0000000000000988","article-title":"Assessment after focal therapy: what is the latest?","volume":"32","author":"Kotamarti","year":"2022","journal-title":"Curr Opin Urol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.010_bib93","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1007\/s00261-020-02577-5","article-title":"Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound","volume":"45","author":"Ghafoor","year":"2020","journal-title":"Abdominal Radiology"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib94","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s13244-014-0359-8","article-title":"Post-treatment MRI aspects of photodynamic therapy for prostate cancer","volume":"5","author":"Kulik","year":"2014","journal-title":"Insights Imaging"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib95","doi-asserted-by":"crossref","first-page":"30.e9","DOI":"10.1016\/j.urolonc.2016.07.015","article-title":"Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity\u2013focused ultrasound focal therapy for localized prostate cancer","volume":"35","author":"Dickinson","year":"2017","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib96","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00345-020-03254-4","article-title":"Current state of image-guided focal therapy for prostate cancer","volume":"39","author":"Tourinho-Barbosa","year":"2021","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.010_bib97","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.010_bib98","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.euf.2022.04.010","article-title":"Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following irreversible electroporation-a multicenter validation study","volume":"8","author":"Geboers","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.010_bib99","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bju.16213","article-title":"Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial","volume":"133","author":"Kaufmann","year":"2024","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.010_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.456","article-title":"Focal therapy of prostate cancer: use of artificial intelligence to define tumour volume and predict treatment outcomes","volume":"6","author":"Brisbane","year":"2024","journal-title":"BJUI Compass"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.010_bib101","article-title":"HoloLens augmented reality system for transperineal free-hand prostate procedures","volume":"10","author":"Li","year":"2023"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009401432500093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009401432500093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:14:06Z","timestamp":1773296046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009401432500093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S009401432500093X"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.010","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Focal Therapies for Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}